GA - 医索

找到约 474 条结果

Use of artificial intelligence-based digital pathology to predictoutcomes for immune checkpoint inhibitor therapy in advancedgastro-esophageal cancer.

医客学院 - 会议报告集

Safety, tolerability and efficacy of 21Pb-DOTAMTATE asa targeted alpha therapy for subjects with unresectableor metastatic somatostatin receptor-expressinggastroenteropancreatic neuroendocrine

医客学院 - 会议报告集

Randomized phase lllll trial of gemcitabine plusnab-paclitaxel versus. concurrentchemoradiotherapy with S-1 as neoadjuvanttreatment for borderline resectable pancreaticcancerGABARNANCE study

医客学院 - 会议报告集

Ramucirumab plus paclitaxel as switch maintenanceversus continuation of oxaliplatin-based chemotherapyin patients with advanced HER2-negative gastric orgastroesophagealjunction cancerthe ARMAN

医客学院 - 会议报告集

Is Timing Everything inGastroesophageal cancers

医客学院 - 会议报告集

Efficacy and Safety of Cadonilimab in Combination withPulocimab and Paclitaxel as Second-ine Therapy in Patientswith Advanced Gastric or Gastroesophageal Junction (GGEJ)Adenocarcinoma who Fail

医客学院 - 会议报告集

The ongoing Antibody-Drug conjugatesRevolution in Breast Cancer

医客学院 - 会议报告集

SACI-0 HR A randomized phase ll trial ofsacituzumab govitecan with or without pembrolizumabin patients with metastatic hormone receptor-positive!HER2-negative breast cancer

医客学院 - 会议报告集

H3B-6545 in women with locally advancedmetastaticestrogen receptor-positive,HER2-negative breast cancer

医客学院 - 会议报告集

First-line inavolisibplacebo palbociclib fulvestrant(InavoPbo Palbo Fulv) in patients (pts) with PiK3cA-mutated.hormone receptor-positive, HER2-negative locally advancedmetastaticbreast cancer

医客学院 - 会议报告集

首页
上一页
1
2
3
4
5
...
47
48
下一页
尾页

今日实时热搜